Back to top
more

scPharmaceuticals (SCPH)

(Delayed Data from NSDQ)

$4.93 USD

4.93
137,212

-0.17 (-3.33%)

Updated Apr 12, 2024 04:00 PM ET

After-Market: $4.95 +0.02 (0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Brokerage Reports

Research for SCPH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

scPharmaceuticals, Inc. [SCPH]

Reports for Purchase

Showing records 1 - 20 ( 37 total )

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

01/05/2024

Daily Note

Pages: 3

Another Good Quarter for Furoscix; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for SCPH 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/09/2023

Company Report

Pages: 5

Launch Metrics Continue to Look Good; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

08/11/2023

Company Report

Pages: 5

Furoscix’s Launch is Off to a Good Start; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

08/02/2023

Daily Note

Pages: 3

An Easy Label Expansion Should Open Up the Opportunity Further; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

07/19/2023

Company Report

Pages: 5

Quick Thoughts Ahead of 2Q

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

06/08/2023

Daily Note

Pages: 3

Strong May Leaves Us Encouraged; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

05/11/2023

Company Report

Pages: 5

Furoscix Delivers Encouraging Early-Launch Indicators; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

03/23/2023

Company Report

Pages: 5

Ready to Hit the Ground Running with Furoscix; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

11/10/2022

Company Report

Pages: 5

Launch Game Plan in Place; Reiterate Buy; Raise PT to $18

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

10/11/2022

Daily Note

Pages: 4

The FDA Says "Yes": Furoscix Receives FDA Approval, Launched Expected in January 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

10/03/2022

Company Report

Pages: 5

HFSA Presentations Highlight Furoscix Value Proposition Ahead of Potential Launch; Reiterate Buy and $15 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

07/13/2022

Daily Note

Pages: 3

AT HOME Study Points the Way

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

05/17/2022

Company Report

Pages: 5

NDA Accepted with October PDUFA Pointing to 4Q Launch

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

04/12/2022

Daily Note

Pages: 3

NDA Gets Refiled With Time to Spare; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

03/23/2022

Company Report

Pages: 5

Resubmission Slated For Tax Day; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

01/27/2022

Industry Report

Pages: 9

Rx for Portfolios, Part 2: Companies With Significant Upcoming Regulatory Decisions

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/10/2021

Company Report

Pages: 5

Furoscix On Track for Potential 4Q22 Commercialization Despite Modest Delay in Resubmission; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for SCPH

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: scPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

08/12/2021

Company Report

Pages: 5

Planned 4Q Resubmission Remains on Track as Furoscix Takes Center Stage at HFSA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party